Akido’s core product, ScopeAI, is a clinical AI system that guides Medical Assistants through patient encounters, scribing conversations, generating clinical reports, preliminary diagnoses, treatment plans, and justification logs. ScopeAI enables a provider to oversee teams of MAs, increasing patient throughput while allowing clinicians to focus on higher-acuity cases. Akido reports ScopeAI visits have delivered 5x more face-to-face time with patients and achieved a 96 NPS score. The company operates a bicoastal Akido Care medical network launched in 2022 that includes more than 240 providers across 26 specialties, roughly 90 clinics, and a patient base of nearly half a million. Akido leverages a proprietary dataset of over 10 million patient case studies and a reinforcement-loop-human-feedback (RLHF) environment to continuously refine ScopeAI. The company plans to use new funding to accelerate development and deployment of ScopeAI and expand into new markets, including a targeted program in New York City for professional rideshare and for-hire drivers.

Total raised

$60M

Funding rounds

1

Latest round

Series B

Latest activity

May 2025